环戊基(2-吡啶基)甲酮 | 157592-43-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 环戊基(2-吡啶基)甲酮
• 英文名称: cyclopentyl(pyridin-2-yl)methanone
• 英文别名: cyclopentyl-2-pyridyl ketone；Cyclopentyl 2-pyridyl ketone
• CAS: 157592-43-3
• 化学式: C₁₁H₁₃NO
• mdl: MFCD07699202
• 分子量: 175.23
• InChiKey: STBHDACSUPGHPA-UHFFFAOYSA-N

物化性质

• 沸点：
  283.2±13.0 °C(Predicted)
• 密度：
  1.102±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  环戊基(2-吡啶基)甲酮 在 sodium cyanotrihydroborate 、 ammonium acetate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (R)-N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
  参考文献：
  名称：

  The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents

  摘要：

  The acetamido and carboxamido substituted 3-(1H-indazol-3-yl)benzenesulfonamides are potent TTK inhibitors. However, they display modest ability to attenuate cancer cell growth; their physicochemical properties, and attendant pharmacokinetic parameters, are not drug-like. By eliminating the polar 3-sulfonamide group and grafting a heterocycle at the 4 position of the phenyl ring, potent inhibitors with oral exposure were obtained. An X-ray cocrystal structure and a refined binding model allowed for a structure guided approach. Systematic optimization resulted in novel TTK inhibitors, namely 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides. Compounds incorporating the 3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl bicyclic system were potent (TTK IC50 < 10 nM, HCT116 GI(50) < 0.1 mu M), displayed low off-target activity (>500X), and microsomal stability (T-1/2 > 30 min). A subset was tested in rodent PK and mouse xenograft models of human cancer. Compound 75 (CFI-401870) recapitulated the phenotype of TTK RNAi, demonstrated in vivo tumor growth inhibition upon oral dosing, and was selected for preclinical evaluation.

  DOI：

  10.1021/jm501740a
• 作为产物：
  描述：

  2--pyridin 在 叔丁基过氧化氢 、 copper(II) choride dihydrate 、 sodium carbonate 、 2,2'-biquinoline-4,4'-dicarboxylic acid dipotassium salt 作用下， 以 水 为溶剂， 生成 环戊基(2-吡啶基)甲酮
  参考文献：
  名称：

  氰基环氧化物的级联合成中溴化氰的双重责任

  摘要：

  已经发现了前所未有的溴化氰反应模式。在碱性条件下，溴化氰同时充当Br中的等效+和CN -至烯醇化的酮转化成良好产率的相应cyanoepoxides。这种独特的反应模式为从容易获得的酮类中稠密取代的氰基环氧化物提供了新的一锅通（见方案）。

  DOI：

  10.1002/anie.201006966

文献信息

• KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：Pauls Heinz W.

  公开号：US20140005167A1

  公开（公告）日：2014-01-02

  The present teachings provide a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

  本教学提供了一种由结构式(I)表示的化合物，或其药用可接受的盐。还描述了药物组合物及其使用方法。
• [EN] INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] COMPOSÉS INDAZOLE UTILISÉS COMME INHIBITEURS DE KINASE ET MÉTHODE DE TRAITEMENT DU CANCER AVEC LESDITS COMPOSÉS
  申请人：UNIV HEALTH NETWORK

  公开号：WO2013053051A1

  公开（公告）日：2013-04-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供了由结构式（I）或（I'）表示的吲唑化合物或其药用可接受的盐。还描述了这些药物组合物及其用作蛋白激酶抑制剂的方法，如对乳腺癌细胞、结肠癌细胞和卵巢癌细胞具有抗癌活性的TTK蛋白激酶、极化样激酶4（PLK4）和极化激酶。
• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASE ET MÉTHODE DE TRAITEMENT DU CANCER À L'AIDE DE CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2014056083A1

  公开（公告）日：2014-04-17

  The invention is a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

  该发明是由结构式（I）表示的化合物或其药学上可接受的盐。这里提供了变量的值。还包括一种含有由结构式（I）表示的化合物和药学上可接受的载体或稀释剂的药物组合物，以及使用结构式（I）的化合物治疗癌症患者的方法。
• Visible Light-Driven Decarboxylative Alkylation of Aldehydes via Electron Donor–Acceptor Complexes of Active Esters
  作者：Fang-Yuan Nie、Yi-Ping Cai、Qin-Hua Song

  DOI：10.1021/acs.joc.1c02586

  日期：2022.1.21

  this paper, we have developed photocatalyst-free and visible light-driven decarboxylative alkylation of pyridinaldehydes. The photochemical reactions are initiated via photoinduced single electron transfer from triethylamine to N-hydroxyphthalimide esters in electron donor–acceptor complexes. This photochemical method can achieve to translate 15 pyridinaldehydes and 11 2-quinolinaldehydes to the corresponding

  有一些从广泛使用的醛到相应的酮的合成方法，但是它们涉及与格氏试剂或过渡金属催化剂的多步反应。在本文中，我们开发了无光催化剂和可见光驱动的吡啶醛脱羧烷基化。光化学反应是通过在电子供体-受体复合物中从三乙胺到N-羟基邻苯二甲酰亚胺酯的光诱导单电子转移引发的。这种光化学方法可以实现将15个吡啶醛和11个2-喹啉醛转化为相应的酮。此外，该策略还可以实现另外两种转化，二硫烷转化为芳基硫化物，苯乙烯砜转化为烷基取代的烯烃。
• Asymmetric Hydroboration of Heteroaryl Ketones by Aluminum Catalysis
  作者：Yury Lebedev、Iuliia Polishchuk、Bholanath Maity、Miguel Dinis Veloso Guerreiro、Luigi Cavallo、Magnus Rueping

  DOI：10.1021/jacs.9b10364

  日期：2019.12.11

  of methyl aluminum complexes bearing chiral biphenol-type ligands were found to be highly active catalysts in the asymmetric reduction of heterocyclic ketones (S/C = 100 - 500, ee up to 99%). The protocol is suitable for a wide range of substrates and has a high tolerance to functional groups. The formed 2-heterocyclic-alcohols are valuable building blocks in drug discovery or can be used as ligands

  发现一系列带有手性双酚型配体的甲基铝配合物是杂环酮不对称还原的高活性催化剂（S/C = 100 - 500，ee 高达 99%）。该协议适用于广泛的底物，并且对官能团具有很高的耐受性。形成的 2-杂环醇是药物发现中的重要组成部分，或可用作不对称催化中的配体。反应中间体的分离和综合表征支持 DFT 计算提出的催化循环。